» Articles » PMID: 24928124

Symptom Onset in Autosomal Dominant Alzheimer Disease: a Systematic Review and Meta-analysis

Abstract

Objective: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD.

Methods: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study.

Results: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10(-16), r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex.

Conclusions: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.

Citing Articles

Accrual of Alzheimer's disease pathology as a function of proximity to parental dementia onset.

Ziukelis E, Mak E, Ritchie C, OBrien J, Aarsland D Alzheimers Dement (Amst). 2025; 17(1):e70092.

PMID: 40018326 PMC: 11865705. DOI: 10.1002/dad2.70092.


Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.

Bateman R, Li Y, McDade E, Llibre-Guerra J, Clifford D, Atri A medRxiv. 2025; .

PMID: 39974075 PMC: 11838922. DOI: 10.1101/2024.10.29.24316289.


Investigating the Aβ and tau pathology in autosomal dominant Alzheimer's disease: insights from hybrid PET/MRI and network mapping.

Zhou Z, Wang Q, Liu L, Wang Q, Zhang X, Li C Alzheimers Res Ther. 2025; 17(1):45.

PMID: 39962560 PMC: 11831832. DOI: 10.1186/s13195-025-01690-1.


Know your brain aging to know your resilience in neurodegenerative diseases.

Ng B, Zetterberg H Brain Commun. 2025; 7(1):fcae467.

PMID: 39816193 PMC: 11734524. DOI: 10.1093/braincomms/fcae467.


Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Rabinovici G, Knopman D, Arbizu J, Benzinger T, Donohoe K, Hansson O Alzheimers Dement. 2025; 21(1):e14338.

PMID: 39776249 PMC: 11772739. DOI: 10.1002/alz.14338.


References
1.
Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

2.
Larner A, Doran M . Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2005; 253(2):139-58. DOI: 10.1007/s00415-005-0019-5. View

3.
Waring S, Doody R, Pavlik V, Massman P, Chan W . Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005; 19(4):178-83. DOI: 10.1097/01.wad.0000189033.35579.2d. View

4.
Mann D, Pickering-Brown S, Takeuchi A, Iwatsubo T . Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol. 2001; 158(6):2165-75. PMC: 1891993. DOI: 10.1016/s0002-9440(10)64688-3. View

5.
Reiman E, Langbaum J, Fleisher A, Caselli R, Chen K, Ayutyanont N . Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-9. PMC: 3343739. DOI: 10.3233/JAD-2011-0059. View